July 01, 2022
Here are the top 5 biosimilar articles for the week of June 27, 2022.
June 30, 2022
June 29, 2022
June 28, 2022
June 27, 2022
June 8th 2022
By Skylar Jeremias
Savings generated from biosimilar utilization could be used to promote innovation for new therapies or funding for more health care services, said Julie M. Reed, the executive director of the Biosimilars Forum.
June 6th 2022
Posters presented at the American Society of Clinical Oncology (ASCO)'s annual meeting showed the successful approaches health systems took to encourage greater adoption of oncology biosimilars.
June 5th 2022
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
June 4th 2022
Results from the European Congress of Rheumatology’s annual meeting revealed that Celltrion’s Remsima SC, a subcutaneous biobetter infliximab product, produced better clinical outcomes compared with the original Remsima, an infliximab biosimilar delivered intravenously.
June 3rd 2022
Here are the top 5 biosimilar articles for the week of May 30, 2022.
June 2nd 2022
Samsung Bioepis and Biogen announced that Byooviz has launched on the US market as the first ranibizumab biosimilar referencing Lucentis, listed at a 40% discount compared with the originator.
June 1st 2022
The FDA approved Fylnetra, the fifth approval for a pegfilgrastim biosimilar in the United States.
May 31st 2022
May brought a number of biosimilar policy updates of all types, including updates on British Columbia's switching program, a new bill that could revamp biosimilar user fee programs, and insight into how companies are shaping their environmental policies around biosimilars.
May 30th 2022
By Laura Joszt
With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability, the US market is entering a new phase of biosimilar use.
May 29th 2022
Combatting misinformation surrounding interchangeability and incentivizing biosimilars are just some of the many things that can be done to ensure patients benefit from biosimilars savings, said Julie M. Reed, the executive director of the Biosimilars Forum.
%20copy.png?w=600&fit=crop&auto=format)
